Fireman B.V. (IFRX)

Mar 20, 2025, 7:30 AM EDT - 5 weeks ago

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Mar 7, 2025, 8:00 AM EST - 7 weeks ago

InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 28, 2025, 9:00 AM EST - 2 months ago

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 25, 2025, 7:30 AM EST - 2 months ago

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Feb 18, 2025, 4:01 PM EST - 2 months ago

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 9:45 PM EST - 2 months ago

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 4:01 PM EST - 2 months ago

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Jan 23, 2025, 7:30 AM EST - 3 months ago

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Jan 15, 2025, 12:30 PM EST - 3 months ago

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Dec 20, 2024, 7:30 AM EST - 4 months ago

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Nov 15, 2024, 7:51 AM EST - 5 months ago

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Nov 8, 2024, 7:30 AM EST - 6 months ago

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 25, 2024, 7:30 AM EDT - 7 months ago

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

Sep 3, 2024, 7:30 AM EDT - 8 months ago

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

Aug 27, 2024, 7:30 AM EDT - 8 months ago

InflaRx Announces Participation in September Investor Events

Aug 8, 2024, 7:30 AM EDT - 9 months ago

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 9 months ago

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

Jun 24, 2024, 8:02 AM EDT - 10 months ago

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

Jun 5, 2024, 12:00 PM EDT - 11 months ago

InflaRx Hosts R&D Event Highlighting the Promise of INF904

May 21, 2024, 2:30 PM EDT - 1 year ago

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

May 8, 2024, 7:30 AM EDT - 1 year ago

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

Mar 21, 2024, 7:00 AM EDT - 1 year ago

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

Mar 19, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

Feb 22, 2024, 7:30 AM EST - 1 year ago

InflaRx Appoints Jan Medina as Head of Investor Relations

Jan 25, 2024, 7:30 AM EST - 1 year ago

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

Jan 4, 2024, 7:00 AM EST - 1 year ago

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

Nov 6, 2023, 7:30 AM EST - 1 year ago

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Nov 1, 2023, 7:30 AM EDT - 1 year ago

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Sep 11, 2023, 7:00 AM EDT - 1 year ago

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Sep 6, 2023, 5:31 PM EDT - 1 year ago

InflaRx: Small German Company Targeting A Rare Indication

Aug 30, 2023, 7:30 AM EDT - 1 year ago

InflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

Aug 10, 2023, 7:30 AM EDT - 1 year ago

InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

Jun 28, 2023, 7:30 AM EDT - 1 year ago

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

Jun 21, 2023, 7:00 AM EDT - 2 years ago

InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients

May 16, 2023, 4:00 AM EDT - 2 years ago

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

May 11, 2023, 7:30 AM EDT - 2 years ago

InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

Apr 18, 2023, 4:01 PM EDT - 2 years ago

InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million

Apr 14, 2023, 4:01 PM EDT - 2 years ago

InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

Apr 11, 2023, 9:08 PM EDT - 2 years ago

InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares

Apr 11, 2023, 4:00 PM EDT - 2 years ago

InflaRx Announces Public Offering of Ordinary Shares

Apr 4, 2023, 2:55 PM EDT - 2 years ago

InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients

Mar 22, 2023, 7:30 AM EDT - 2 years ago

InflaRx Reports Full Year 2022 Financial and Operating Results

Jan 5, 2023, 7:30 AM EST - 2 years ago

InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients

Dec 26, 2022, 3:10 AM EST - 2 years ago

Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck

EVGN MRK PFE

Dec 21, 2022, 7:30 AM EST - 2 years ago

InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19

Dec 14, 2022, 2:34 AM EST - 2 years ago

InflaRx: On Watch For A Buy During Tax Loss Selling Season

Nov 9, 2022, 7:40 AM EST - 2 years ago

InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904

Nov 9, 2022, 7:30 AM EST - 2 years ago

InflaRx Reports Third Quarter 2022 Financial & Operating Results

Sep 29, 2022, 7:30 AM EDT - 2 years ago

InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients